<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802928</url>
  </required_header>
  <id_info>
    <org_study_id>2007-003387-22</org_study_id>
    <nct_id>NCT04802928</nct_id>
  </id_info>
  <brief_title>Healing of Ischemic Leg Ulcers in Patients Treated With iSONIAzid</brief_title>
  <acronym>SONIA</acronym>
  <official_title>Healing of Ischemic Leg Ulcers: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharma 2100</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharma 2100</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to study the healing effect of an oral drug (isoniazid)&#xD;
      in patients with ischemic (arterial) leg ulcers defined by a systolic toe pressure &lt;40 mm Hg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of arterial ulcers is problematic. Previous pharmaceutical interventions with for&#xD;
      example prostaglandins have produced only limited beneficial effects but have been associated&#xD;
      with frequent adverse effects. Positive effects of isoniazid have been observed in a&#xD;
      preclinical model of ischemic wound healing (Weinreich et al. Surgery 2010).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Patients fulfilling the criteria could not be found.&#xD;
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">November 2008</completion_date>
  <primary_completion_date type="Anticipated">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage change of ulcer area 8 weeks after initiation of therapy.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The wound area is measured at week 0 (A0) and at 8 weeks (A8). From these measurements, the percentage (%) change of the wound area in relation to the start time (week 0) is determined from the following formula: (A0-A8)/A0*100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain is evaluated by visual analogue scale (VAS).</measure>
    <time_frame>8 weeks</time_frame>
    <description>The visual analogue scale ranges from 0 mm (minimum) to 100 mm (maximum), where the lower value the better is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of suspected unexpected serious adverse reactions (SUSAR) and serious adverse events (SAE)</measure>
    <time_frame>8 weeks</time_frame>
    <description>the number of SUSAR and SAE occurring over the 8-week treatment period is recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Arterial Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid 300 milligram</intervention_name>
    <description>Tablets 150 milligram b.i.d.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ischemic leg ulcers unsuitable for vascular surgical intervention&#xD;
&#xD;
          -  Systolic toe pressure &lt; 40 mm Hg&#xD;
&#xD;
          -  Ulcer duration &gt; 3 months&#xD;
&#xD;
          -  Ulcer area: 1-20 cm2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  B-Hb &lt; 6 mmol/l&#xD;
&#xD;
          -  Aspartate transaminase &gt; 50 U/l&#xD;
&#xD;
          -  Diabetes mellitus &gt; 10%HbA1c&#xD;
&#xD;
          -  Usage of more than 10 mg prednisolone daily within the last 30 days&#xD;
&#xD;
          -  Usage of cytotoxic agents with the last 3 months&#xD;
&#xD;
          -  Usage of rifampicin, phenytoin, carbamazepin, theophylline, benzodiazepines (diazepam,&#xD;
             triazolam), stavudine and/or valproat&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Hereditary galactose intolerance&#xD;
&#xD;
          -  Hypersensitive to isoniazid or for one or more of the filling substances (magnesium&#xD;
             stearate, povidone, talcum, lactose and starch)&#xD;
&#xD;
          -  Cellulitis or deep infection (osteomyelitis and/or tendonitis) related to the ulcer&#xD;
&#xD;
          -  Gangrene&#xD;
&#xD;
          -  Participation in clinical trials within the last 7 days&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Women of child bearing potential who decline to use contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tonny Karlsmark, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pharma 2100</investigator_affiliation>
    <investigator_full_name>Magnus Agren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

